Is axitinib/axitinib already on the market?

Axitinib/Axitinib is a second-generation tyrosine kinase inhibitor that mainly works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2 and VEGFR-3). This mechanism enables axitinib to effectively block tumor angiogenesis, thereby inhibiting its growth and metastasis. Studies have shown that axitinib is 50 to 450 times more effective than first-generation VEGFR inhibitors, and therefore has demonstrated good therapeutic effects in clinical applications.

Axitinib has the chemical structure of an indazole derivative and is commonly sold under the trade name"Inlyta" and is available in an oral dosage form. Since 2012, axitinib has been approved for the treatment of renal cell carcinoma in many countries and regions. Specifically, the drug was first approved by the US Food and Drug Administration (FDA) in January 2012, followed by the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in September of the same year. In addition, axitinib was approved by the Australian Therapeutic Goods Administration (TGA) in July 2012.

In China, axitinib was approved by the State Food and Drug Administration to enter the market in April 2015, with the trade name "Inlida". This listing provides a new treatment option for patients with renal cell carcinoma, especially those whose disease has progressed after first-line treatment. The efficacy is particularly significant. Clinical studies have shown that axitinib has a positive effect in delaying disease progression and improving patients' quality of life.

Overall, the launch of axitinib not only enriches the treatment options for renal cell carcinoma, but also brings new hope to patients. As the drug is further studied, its potential for use in other types of cancer may be explored in the future, providing more treatment options for a wider patient population.

Reference materials:https://en.wikipedia.org/wiki/Axitinib